Update on Vyvanse (lisdexamfetamine dimesilate) investigation

Our investigation into concerns about Vyvanse’s potential lack of effectiveness, quality and safety found no issues of concern.

We began an investigation in March 2025 following an unexpected increase in the number of adverse event reports for Vyvanse (lisdexamfetamine dimesilate), including concerns about lack of effectiveness, quality and safety.

Our testing found that all batches met the specified quality requirements.

The increased reporting started in March 2025 and appeared to be stimulated by social media commentary.

Vyvanse is used for the treatment of attention deficit hyperactivity disorder (ADHD), and moderate to severe binge eating disorder in adults when nonpharmacological treatment is unsuccessful or unavailable.

For more detailed information written for health professionals, see this Medicines Safety Update article.